Paradigm Genetics, Inc. has signed a broad collaboration agreement with Monsanto Company in the field of functional genomics. Under the terms of the agreement, Paradigm will develop functional genomics data by analyzing the product of Monsanto's gene sequencing, bioinformatics and functional genomics research, creating a product discovery platform for commercialization. Under terms of the agreement, Paradigm will receive $55 million in committed payments. Additional financial terms were not disclosed.

Paradigm brings to this collaboration its expertise in gene function analysis and bioinformatics. Paradigm's high-throughput analysis methodology is comprised of a series of proprietary analytical processes combined with a computerized knowledge base of plant and fungal functional genomics.

Monsanto has a robust genomics network, including one of the largest gene sequencing and bioinformatics operations in the world.

"We believe this collaboration with Monsanto, a leader in the commercialization of novel agricultural products, validates Paradigm's industrial scale gene function platform,'' said John Ryals, Ph.D., CEO and President of Paradigm. "It also allows us the financial resources to focus our in-house efforts on other applications of the technology, in areas such as human health, nutrition, industrial applications and crop production.''

Paradigm Genetics is harnessing the power of biology for global crop production, nutrition, and human health. By combining biology with computer technology, the company has become a leader in bioinformatics as it relates to gene function. Paradigm has developed a proprietary functional genomics system that integrates gene discovery, gene function determination, and gene use identification. The company intends to leverage its gene function identification and bioinformatics technologies to discover better and safer compounds to protect crops against disease, weeds, and insect pests; develop more efficacious and environmentally-friendly plant nutrition products; create novel food products to improve human health; develop botanicals and human pharmaceuticals; and discover novel antimicrobial compounds for human use. 

Company news release
N2428